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Abstract
Background: Whole genome amplification (WGA) methods allow diagnostic laboratories to
overcome the common problem of insufficient DNA in patient specimens. Further, body fluid
samples useful for cancer early detection are often difficult to amplify with traditional PCR
methods. In this first application of WGA on the entire human mitochondrial genome, we
compared the accuracy of mitochondrial DNA (mtDNA) sequence analysis after WGA to that
performed without genome amplification. We applied the method to a small group of cancer cases
and controls and demonstrated that WGA is capable of increasing the yield of starting DNA
material with identical genetic sequence.
Methods: DNA was isolated from clinical samples and sent to NIST. Samples were amplified by
PCR and those with no visible amplification were re-amplified using the Multiple Displacement
Amplificaiton technique of whole genome amplification. All samples were analyzed by mitochip for
mitochondrial DNA sequence to compare sequence concordance of the WGA samples with
respect to native DNA. Real-Time PCR analysis was conducted to determine the level of WGA
amplification for both nuclear and mtDNA.
Results: In total, 19 samples were compared and the concordance rate between WGA and native
mtDNA sequences was 99.995%. All of the cancer associated mutations in the native mtDNA were
detected in the WGA amplified material and heteroplasmies in the native mtDNA were detected
with high fidelity in the WGA material. In addition to the native mtDNA sequence present in the
sample, 13 new heteroplasmies were detected in the WGA material.
Conclusion: Genetic screening of mtDNA amplified by WGA is applicable for the detection of
cancer associated mutations. Our results show the feasibility of this method for: 1) increasing the
amount of DNA available for analysis, 2) recovering the identical mtDNA sequence, 3) accurately
detecting mtDNA point mutations associated with cancer.
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Background
It is often the case that an insufficient quantity of DNA can
be isolated from clinical specimens and controls for full
genome analysis. The quantity of DNA is particularly lim-
ited in patient tumor specimens, most notably in early
tumors with limited mass and therefore, insufficient DNA
may be available to perform the multiple analyses
required for full genome screening [1-4]. Whole genome
amplification (WGA) methods have been developed to
solve the problem of insufficient quantities of DNA [5,6].
Using these technologies, investigators have been success-
ful in applying genome scanning technologies to patient
cohort samples collected years ago that are not recovera-
ble by other means [7]. WGA is useful for amplification of
DNA from stored histology slides, tissue samples, and
blood stains, including amplification from single sperm
[8-10].
Two common methods used for WGA are multiple-dis-
placement amplification (MDA) and library synthesis
from fragmented genomic DNA (gDNA). MDA uses the
highly processive Ø29 DNA polymerase and random exo-
nuclease-resistant primers in an isothermal amplification
reaction [11]; this method is based on strand-displace-
ment synthesis [12,13]. A second commonly used
method converts randomly fragmented gDNA into a
library of DNA fragments of defined size; this library can
be effectively amplified several thousand-fold using a
high-fidelity DNA polymerase and can be re-amplified to
achieve a final amplification of over a million fold with-
out degradation of representation [14]. Both of these
methods produce material suitable for downstream mul-
tiplex analyses [15,16].
An advantage of the MDA method is the generation of sig-
nificant quantities of large fragments of amplified gDNA
in a single step. The library-based method has the advan-
tage that it enables the creation of whole-genome DNA
libraries from degraded as well as intact DNA samples.
However, care should be exercised to rule out locus and
allele dropouts in the WGA product. For efficient amplifi-
cation, the template should be a minimum of 2000 base
pairs in length and optimally greater than 10,000. A min-
imum of 10 ng of DNA is required [17]. For the study
described in this paper, the MDA method was used due to
ease of use and perceived integrity of the circular mito-
chondrial DNA. The conclusions from these studies are
that whole genome amplification provides a useful tool
when there are limited quantities of DNA.
Although clinical testing of genomic DNA amplified with
WGA techniques demonstrated excellent concordance for
the detection of point mutations [18,19], WGA has not
been widely accepted because of concerns about replica-
tion accuracy. Further, papers reporting the use of WGA
techniques have focused on the evaluation of the tech-
nique rather than on the accuracy with patient specimens.
There are also a variety of factors to note when comparing
WGA studies, e.g. tissue acquisition, fixation, sectioning,
etc [11]. Although mtDNA is more abundant than nuclear
DNA, the same limitations are relevant with mtDNA.
Early detection of disease associated mutations frequently
requires the analysis of matched body fluids samples.
Often body fluids that are used to assess the presence of
cancer in remote sights contain degraded DNA or very low
quantity. To validate the usefulness of body fluids to
potentially replace tumor tissue as a source of mtDNA, we
identified a WGA system that fulfills our requirements
with respect to product yield and quality and have opti-
mized this WGA method for the entire human mitochon-
drial genome. Prior studies using WGA for mtDNA
reported on the control region, which only accounts for
6% of the mitochondrial genome [20,21]. In our study,
sequence concordance for native genomic DNA and
WGA-amplified DNA was analyzed using the Affymetrix
GeneChip®  mitochondrial CustomSeq®  resequencing
microarray, versions 1 and 2. These arrays have increased
sensitivity over traditional fluorescent DNA sequencing
for the detection of mixed bases, or heteroplasmies [22].
Overall, the sequence identity between native and WGA
material was 99.9995%. Further, for disease associated
mutations (genetic differences between tumor tissue and
matched blood samples) WGA correctly identified 100%
of the mutations. Heteroplasmies were accurately
detected using WGA. Our results show that WGA is a reli-
able method for amplifying mtDNA from body fluids
(sputum), blood and tumor tissue.
Methods
DNA isolation: blood and matched tumor
Paired normal and tumor specimens were collected after
surgical resection with prior consent from patients in the
Johns Hopkins University Hospital. DNA samples were
provided by Dr. David Sidransky at the Johns Hopkins
School of Medicine. Samples were collected primarily
from early stage (stage IA to IIB) tumors. DNA was
extracted from micro-dissected tumor tissue obtained
from cryostat-embedded snap-frozen sections. Tumor sec-
tions were digested with 1% SDS/Proteinase K, and DNA
extracted by phenol, chloroform and ethanol precipitated.
Tumor samples were obtained from males and females.
DNA isolation: non cancer samples
DNA from blood and sputum from 8 individuals in Tri-
zol® Reagent was provided by Dr. William Rom New York
University School of Medicine. The DNA was recovered
using the manufacturer's protocol (Invitrogen Corp.,
Carlsbad, CA). Patients were considered cancer free based
upon spiral CT analysis. MtDNA from three matchedBMC Medical Genetics 2008, 9:7 http://www.biomedcentral.com/1471-2350/9/7
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blood and sputum samples, and one un-matched blood
and 4 unmatched sputums were analyzed from these eight
individuals. The remaining samples from these individu-
als (4 blood samples and 1 sputum) could not be ana-
lyzed without WGA amplification.
PCR amplification: Repli-g Whole Genome Amplification 
(WGA)
A REPLI-g midi kit (Qiagen Inc., Valencia, CA) was used
to amplify total DNA. The REPLI-g kit amplifies isother-
mally at 30°C using Ø29 DNA polymerase with 3' → 5'
exonuclease proofreading activity and multiple displace-
ment amplification. The published "Whole Genome
Amplification Using Purified Genomic DNA" protocol
was followed. Briefly, buffers D1-denaturation buffer and
N1-neutralization buffer were made in accordance with
the protocol. Template DNA (2.5 μL), 2.5 μL of buffer D1
was added and incubated at room temp. for 3 minutes;
then 5 μL of buffer N1 was added. Forty microliters of the
replication mix (10 μL H2O, 29 μL REPLI-g Midi Reaction
Buffer, 0.5 μL REPLI-g Midi DNA Polymerase) was added
on ice to the denatured DNA for a total volume of 50 μL.
The mix was incubated for 16 hrs at 30°C. Polymerase
activity was stopped by a 5 minute incubation at 65°C.
WGA DNA was then reamplified (1 μL WGA per PCR reac-
tion) using the 3 MitoChip primer sets and the Affyme-
trix/JHMI protocol [23].
Real-time PCR analysis
Quantities of the native template and WGA nuclear and
mtDNA were measured by Real-Time PCR on a Chromo4
system (Bio-Rad Laboratories Inc., Hercules, CA). The
TNF gene was used as a nuclear DNA marker and
12SrRNA was used as a mtDNA marker as described [24].
Briefly each PCR reaction contained: 12.5 μL 2x iQ SYBR
Green Supermix (Bio-Rad), forward and reverse primers
(125 nM final concentration), template DNA and water to
a final volume of 25 μL. Thermal cycling conditions: (1
cycle) 95°C for 3 min, (45 cycles): 95°C for 30 sec,
61.5°C for 30 sec, 72°C for 30 sec, (1 cycle) 72°C for 10
min, melt curve 50°C to 105°C increasing at 1°C inter-
vals with a 3 sec hold. The NIST Human DNA Quantita-
tion Standard (SRM 2372) was used to calibrate the
standard curve of the quantitative PCR assay. Quantitative
PCR values were used to calculate the mass of nuclear
DNA and mtDNA added to the WGA reaction, the
amount of amplified nuclear and mtDNA after WGA, and
the fold amplification of nuclear and mtDNA obtained by
using WGA.
PCR amplification
Three matched primer sets were used to amplify the DNA
for hybridization onto the Affymetrix GeneChip® mito-
chondrial CustomSeq® Resequencing microarray. In our
initial studies, version 1 arrays were used to analyze DNAs
from 8 non-cancer individuals and 6 cancer patients. After
the release of the version 2 array, DNAs from the 6 cancer
patients were reanalyzed with the GeneChip®  Human
Mitochondrial Resequencing Array 2. The primer sets
together amplified the entire mitochondrial genome.
Quality control, as outlined previously was followed [25].
Briefly, for the MitoChip, the mtDNA template (20 ng up
to 10 μL), 0.75 μL of forward and reverse primers (10
μM), 0.5 μL LA Taq polymerase (TaKara), 5 μLPCR buffer,
8 μL dNTP (2.5 mM each) and dH2O up to a total reaction
volume of 50 μL. Thermal cycling conditions were as fol-
lows: pre-amplification denaturation: (1 cycle), 94°C for
2 min; amplification (30 cycles): 94°C for 15 s; annealing
and elongation, 68°C for 7 min; final elongation (1
cycle), 68°C for 12 min; 4°C hold. Amplification of PCR
products was confirmed by gel electrophoresis on a 0.8%
agarose gel. PCR amplification products were analyzed for
quality and quantity by spectrophotometric methods as
described in GeneChip CustomSeq™ Resequencing Array
Protocol Version 2.
PCR cleanup: MitoChip
PCR clean up was conducted using the QIAquick 96 well
vacuum plate manifold and protocol [26]. DNAs were
eluted in 65 μL of DNAse/RNAse free water.
MitoChip protocol
The GeneChip® CustomSeq® Resequencing Array Protocol
Version 2.0 was followed with a few modifications.
Briefly, three amplicons representing the mitochondrial
genome were pooled at equi-molar concentrations. The
pooled PCR amplification products were fragmented,
labeled, hybridized, washed and scanned. The total quan-
tity of DNA applied to the array was 0.62 μg. Fragmenta-
tion of the pooled DNAs was conducted using 0.15 units
of Fragmentation reagent (0.033 μL) per sample at 37°C
for 35 minutes followed by 95°C for 15 minutes to inac-
tivate the enzyme. The fragments were labeled with 30
units of TdT using the Affymetrix GeneChip® DNA Labe-
ling Reagent containing a proprietary biotinylated label.
Labeling was carried out at 37°C for 90 minutes followed
by 95°C for 15 minutes. The hybridization cocktail
including the separately prepared control fragments were
hybridized for 16 to 18 hours at 45°C rotating at 60 rpm.
Arrays were scanned on a GeneChip® Scanner 3000G7
Scanner, and analyzed with GeneChip® Operating Soft-
ware (GCOS v1.4) and GeneChip®  Sequence Analysis
Software (GSEQ v4.0).
MitoChip sequence interpretation
Final analysis of all data was conducted using Affymetrix
software GCOS v1.4 and GSEQ v4.0 in addition to an in
house analysis program. Probe intensities for each muta-
tion reported by the software was examined on both for-BMC Medical Genetics 2008, 9:7 http://www.biomedcentral.com/1471-2350/9/7
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ward and reverse stands. Heteroplasmies were only
confirmed and reported if present on both strands.
Results
Sequencing of mtDNA from tumor, blood and body flu-
ids from the same individuals was carried out to deter-
mine whether body fluids could be used to detect cancer.
We were frequently unable to compare all three speci-
mens as there was insufficient DNA available for sequenc-
ing in one or more samples [4,22,27]. However, WGA
provided ample DNA for these experiments. Thirteen of
twenty-four non-cancer specimens could not be amplified
by PCR, but all twenty-four specimens were amplifiable
after using WGA. This is shown in Figure 1 for three of
thirteen non-cancer samples whose native DNA was not
amplifiable by PCR (panel A), and PCR products of the
correct length for the same specimens post WGA (panel
B). To determine whether WGA altered the sequence of
mtDNA, we compared mtDNA sequences in unamplified
mtDNA (native) and WGA mtDNA for both cancer and
non-cancer samples.
Fold amplification of nuclear and mtDNA by WGA
Real-Time PCR measurements were used to determine the
extent of WGA amplification of specimen DNAs. Because
WGA amplifies total DNA present separate markers were
used to determine quantities and fold amplification of
nuclear (TNF) and mtDNA (12SrRNA). For all samples,
there was at least a 120 fold amplification of nuclear DNA
and 133 fold amplification of mtDNA after WGA; with
WGA outputs of at least 880 ng of nuclear DNA and 1,260
ng of mtDNA (Table 1). The extent of amplification
roughly correlates with the amount of input DNA in an
Table 1: Real-Time PCR: nuclear and mtDNA native and WGA samples
Native input 
nuclear DNA (ng)
Nuclear DNA in 50 
uL WGA (ng)
Fold nuclear DNA 
amplification by WGA
mtDNA input 
nuclear DNA (ng)
mtDNA in 50 uL 
WGA (ng)
Fold mtDNA 
amplification by 
WGA
CB 4 6.80E-01 2.80E+04 4.12E+04 1.28E+00 1.38E+04 1.08E+04 CB 4
CB 1 1.65E+00 1.98E+04 1.20E+04 2.38E+00 3.66E+04 1.54E+04 CB 1
CS 3 2.03E+00 1.07E+04 5.25E+03 3.50E+00 2.82E+03 8.05E+02 CS 6
CS 6 2.05E+00 8.38E+03 4.08E+03 7.65E+00 2.94E+03 3.84E+02 CS 8
CS 2 4.28E+00 1.11E+04 2.58E+03 8.12E+00 1.50E+04 1.85E+03 CS 1
CS 1 5.14E+00 3.47E+03 6.75E+02 8.13E+00 1.93E+03 2.38E+02 CS 3
CS 8 7.29E+00 6.15E+03 8.44E+02 1.29E+01 5.47E+03 4.24E+02 CS 2
CB 2 1.23E+01 6.37E+03 5.19E+02 1.26E+02 1.17E+05 9.24E+02 CS 5
CB 3 6.52E+01 7.82E+03 1.20E+02 2.15E+02 3.07E+04 1.43E+02 CB 2
CS 5 9.37E+01 2.83E+04 3.02E+02 2.92E+02 3.87E+04 1.33E+02 CB 3
CS 7 n/a 5.82E+03 n/a n/a 3.06E+03 n/a CS 7
PB 2 1.46E-01 9.06E+03 6.19E+04 0.04 8.33E+03 2.10E+05 PB 4
PB 4 1.56E-01 7.43E+03 4.75E+04 0.05 2.84E+03 6.08E+04 PB 2
PT 3 1.70E-01 8.82E+02 5.19E+03 0.26 1.26E+03 4.91E+03 PB 1
PT 2 2.26E-01 5.47E+03 2.42E+04 0.27 4.32E+03 1.60E+04 PB 3
PB 3 2.36E-01 2.95E+03 1.25E+04 0.41 8.03E+03 1.94E+04 PT 2
PB 1 4.77E-01 2.85E+03 5.97E+03 0.77 3.51E+03 4.58E+03 PT 3
PT 1 5.33E-01 4.41E+03 8.27E+03 1.45 4.08E+03 2.81E+03 PT 1
PB 5 n/a 4.59E+03 n/a n/a 1.60E+04 n/a PB 5
n/a: insufficient DNA present for assa
Gel image after PCR amplification of the three mtDNA  primer sets used in this study Figure 1
Gel image after PCR amplification of the three mtDNA 
primer sets used in this study. DNA from three samples 
(1–3) were amplified without (panel A) and after WGA 
(panel B), then separated on a 0.8% agarose E-Gel (Invitro-
gen). Lanes 1–3: sample 1, lanes 4–6: sample 2, and lanes 7–8: 
sample 3. For all three samples the PCR products are shown 
in the following order on the gel: 6185 bp product, 6015 bp 
product and 5063 bp product.BMC Medical Genetics 2008, 9:7 http://www.biomedcentral.com/1471-2350/9/7
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inverse relationship, where the samples with less input
DNA had higher fold amplification than the samples with
higher amounts of input DNA.
Native vs. WGA mtDNA sequence: non cancer blood and 
sputum
Native mtDNA and WGA mtDNA from three matched
blood and sputum samples from non cancer individuals
were sequenced on the version 1 Mitochip (n = 6). These
DNA samples were isolated using a different method (Tri-
zol) than that used for the cancer patient DNAs. There was
no difference in the call rate of the chips for native mtDNA
(99.38% +/-0.28) and WGA mtDNA (99.42% +/-0.26)
(Table 2 and Figure 2). Boxplots are used to represent the
call rate data [28]. The box represents the interquartile
range of the data with the "wiskers" stretching from the
box defining the maximum and minimum data points.
The horizontal line within the box is the median point of
the dataset. Of the six genomes compared, one homoplas-
mic difference was identified between the native and
WGA sequences (Table 2) where the native sequence was
a T and the WGA material was a C. Thus, sequence identity
of 99.9994% for the 6 native and WGA samples was
obtained.
The mtDNA sequences from an additional 5 samples (1
blood and 4 sputums) from non cancer individuals were
also analyzed on the version 2 array. The sequence com-
parison of native and WGA mtDNA resulted in 99.9994%
concordance between the sequences, with a discordance
of callable bases of 0.00054%. For 1 nucleotide position
in a single WGA sample, a heteroplasmy was detected that
consisted of the native nucleotide A, plus a base transition
G (Table 2).
Native vs. WGA mtDNA sequence: blood and tumor 
patient samples
Blood and tumor samples from four lung cancer patients
were amplified (without WGA) with three primer sets and
sequenced on the version 1 mitochondrial resequencing
array with an average sequence call rate of 99.61% +/-
0.16. These same 8 samples were amplified (with and
without WGA) and sequenced on the version 2 mitochon-
drial resequencing array. Mitochondrial sequence average
call rates for native and WGA samples were 99.49% +/-
0.19 and WGA 99.23% +/-0.15 respectively (Table 3, Fig-
ure 3). The comparison of native and WGA mtDNA
sequences from five blood and three tumor samples (n =
8) identified a 99.995% concordance between native and
WGA sequences and a discordance of callable bases of
Boxplots of call rates obtained from version 1 mitochondrial  resequencing arrays for 11 samples Figure 2
Boxplots of call rates obtained from version 1 mitochondrial 
resequencing arrays for 11 samples. (1) Native blood and 
sputum DNAs from non-cancer individuals and (2) WGA 
blood and sputum DNAs using the native DNAs in 1.
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Table 2: Controls: native vs. WGA
Controls Native vs. WGA
Sample Conflicts Type Position
CB 1 0 n/a
CB 2 1 Homo T11471C
CB 3 0 n/a
CB 4 0 n/a
CS 1 0 n/a
CS 2 0 n/a
CS 3 0 n/a
CS 5 0 n/a
CS 6 1 Hetero A10750R
CS 7 0 n/a
CS 8 0 n/a
* Control Blood + Control Sputum
Table 3: Patient samples: native vs. WGA
Native vs. WGA
Sample Conflicts Type
PB 1 1 Hetero
PB 2 2 Hetero
PB 3 3 Hetero
PB 4 3 Hetero
PB 5 0 n/a
PT 1 0 n/a
PT 2 4 Hetero
PT 3 0 n/a
* Patient Blood + Patient TumorBMC Medical Genetics 2008, 9:7 http://www.biomedcentral.com/1471-2350/9/7
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.00495%. There was no difference in the native and WGA
mtDNA sequences for three of the samples. Five of the 8
samples had on average 2 heteroplasmy calls accounting
for 0.005% sequence disagreement (Table 4). For twelve
of the base call differences, there was a homoplasmic call
in the native sample (the wildtype sequence information)
and there was a heteroplasmy for the WGA sample. In one
case there was the opposite of this, with a heteroplasmy
detected in the native sample and a homoplasmic call
agreeing with the reference sequence, tiled on the Mito-
Chip, in the WGA sample.
Comparison of version 1 and version 2 MitoChip arrays
Previous studies demonstrated that the Affymetrix version
1 CustomSeq® Resequencing array for human mitochon-
drial DNA was an accurate and highly sensitive tool for
mtDNA sequencing, particularly in detecting heteroplas-
mies [23]. However, this array contained only the mito-
chondrial DNA coding region (nts 577-16023 of the
16,568 bp genome). Subsequently, Affymetrix developed
a second generation chip that contains the entire mtDNA
genome. This second generation array was determined to
have call rates comparable to the version 1 array, and a
chip to chip error rate of 0.00328% with potentially
higher sensitivity than the version 1 array due to the addi-
tional sequence coverage [29].
To verify that the sequence data obtained from version 1
and version 2 mitochondrial resequencing arrays are com-
parable, DNA s from 6 cancer patients were analyzed on
both versions of the array. In total, 10 samples (6 bloods
and 4 tumors) were sequenced on both arrays, as insuffi-
cient quantities of DNA were available to amplify 2 tumor
samples. All sequences were first compared to the RCRS
sequence to generate SNP reports. The reports for the
same samples were compared for each version, and all dif-
ferent calls were evaluated. There was no significant differ-
ence between the average number of calls generated for
each genome on the two arrays; 99.66% +/-0.15 for v1
arrays, and 99.47% +/-0.29 for v2 arrays (Table 5, Figure
4). The comparison showed that the sequences obtained
from version 1 and version 2 arrays are 99.999% identical,
with a total of 2 differences identified between the 2 ver-
sions of the array. The discordance between version 1 and
version 2 chips of the same sample DNA was 0.00065%.
As stated in the materials and methods, heteroplasmic
calls were only made if the heteroplasmy was detected on
both sense and antisense strands.
Table 5: Version1 vs Version 2 Arrays
v1 vs. v2
Sample Conflicts Type Position
PB 1 0 n/a
PB 2 0 n/a
PB 3 0 n/a
PB 4 1 hetero A14185R
PB 5 0 n/a
PB 6 1 hetero C7256Y
PT 1 0 n/a
PT 2 0 n/a
PT 3 0 n/a
PT 4 0 n/a
Boxplots of call rates obtained from version 2 mitochondrial  resequencing arrays for 8 samples Figure 3
Boxplots of call rates obtained from version 2 mitochondrial 
resequencing arrays for 8 samples. (1) Native blood and 
tumor DNAs from Lung cancer patients and (2) WGA blood 
and tumor DNAs using the native DNAs in 1.
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Table 4: Discrepant calls
Mito Pos Ref Native WGA
PB1 8723 G * R
PB2 7553 A * R
10450 T * Y
PB3 1350 G * R
6365 T * Y
12047 T * Y
PB4 189 A * R
6365 T * Y
14185 A R *
PT2 2783 A * R
2966 T * Y
6102 T * Y
8725 A * RBMC Medical Genetics 2008, 9:7 http://www.biomedcentral.com/1471-2350/9/7
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Discussion
The ability to detect cancer associated mutations in clini-
cal samples is frequently limited by the quantity of DNA
obtained from each sample. Limited DNA yield along
with assay requirements often result in insufficient sample
to replicate results. This can be especially problematic
with archival of samples with unique characteristics.
Whole Genome Amplification as a means of robust,
highly accurate amplification of small concentrations of
DNA is a very attractive tool for increasing the success rate
of diagnostic testing.
Alterations in mtDNA have been shown to be potential
biomarkers for cancer detection [2,4,24,30]. In this study,
we evaluated the utility of Multiple Strand Displacement
Whole Genome Amplification as a means of generating
large quantities of mtDNA from total DNA without
changing the mtDNA sequence due to amplification error
or biasing amplification towards a subpopulation. Over-
all, we found that WGA does amplify nuclear and mtDNA
100 to greater than 10,000 fold and that WGA-amplified
mtDNA was of equivalent performance as native mtDNA,
with all the disease associated mutations successfully
identified in cancer samples with respect to normal con-
trols. Additional low level base transitions were amplified
along with the native sequence, appearing as mixtures
(heteroplasmic calls). Thus, WGA allows high fidelity,
high yield whole genome amplification supporting its use
in mitochondrial DNA testing for clinical and research
applications when tissue/DNA samples are limiting.
MtDNA sequences obtained from the different versions of
the array were compared using the same input DNA. This
showed there is no significant difference between
sequences obtained from either the version 1 or 2 of the
array. The analysis confirmed 6 of 8 sequences to be 100%
identical and two samples to have one heteroplasmic dif-
ference each resulting in 99.999% sequence identity.
Sequence comparisons between native mtDNA sample
and WGA-amplified mtDNA were conducted on eleven
samples from non-cancer individuals using the version 1
array. Nine comparisons resulted in no differences
between the native and WGA sequences. Confidence in
the WGA sequence data was strengthened by the WGA
sequence correctly identifying 8 heteroplasmies present in
the native sample, demonstrating that bias towards one of
the two populations did not occur.
The same results were obtained for blood and tumor DNA
from cancer patients as were seen in the non-cancer sam-
ples. The sequence comparisons between the eight native
mtDNA samples (5 bloods and 3 tumors) and their
respective WGA counterparts resulted in a 99.995% corre-
lation between corresponding sequences, similar to the
99.9994% concordance seen in the comparison of native
and WGA non-cancer samples. In addition, the number of
bases recovered after mtDNA sequencing of WGA DNA
was very high: 99.42% for non-cancer samples and
99.23% for cancer samples. In addition the discordance
between the callable bases of native and WGA samples
ranged from 0.00054% to 0.00495%, which is very com-
parable to the rate of 0.00328% observed previously for
tumor samples sequenced in triplicate on the version 2
microarray [30]. These results demonstrate that the micro-
array technology used in this study, in conjunction with
WGA amplification, should be considered as having the
same high performance capabilities as traditional fluores-
cent based capillary electrophoresis.
Conclusion
Of the 19 samples examined in this study whole genome
amplification by MDA was used to amplify nuclear and
mtDNA from clinical samples at a rate of 120 to greater
than 10,000 fold. Fold amplification is inversely propor-
tional to the input DNA added to the WGA reaction. The
mtDNA sequences of the 19 samples showed 15 instances
where the base call of the native sample disagreed with the
base call of the matched WGA sample, an event occurring
at less than 0.005%. Fourteen of the discrepant calls were
heteroplasmic calls, with 13 of 14 being present in the
WGA sample sequence and the native sample a homo-
plasmic base identical to the reference sequence. In all
instances, the heteroplasmy in the WGA sample was a
transition; containing the same base identified in the
native sample as well as the other purine or pyrimidine.
Boxplots of call rates for 10 native blood and tumor DNAs  sequenced on both the version 1 and version 2 mitochon- drial resequencing array Figure 4
Boxplots of call rates for 10 native blood and tumor DNAs 
sequenced on both the version 1 and version 2 mitochon-
drial resequencing array. (1) Samples sequenced on version 1 
array (2) Samples sequenced on version 2 array.
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There was a single instance of a heteroplasmy being
present in the native sample, but absent from the WGA
material (Table 2). It is unclear whether or not the hetero-
plasmies detected after WGA were present in the native
sample in very low abundance and below the detection
limit of the sequencing technology, or if these popula-
tions were introduced erroneously by the WGA technol-
ogy. Heteroplasmies detected in samples that have been
pre-amplified by WGA should therefore be carefully
examined to confirm their authenticity.
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